NEJM· @NEJM · X·· 15 小时前评分90
正文 · 原文
Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://nej.md/4iveIgW
@myESMO
2684 浏览 · 12 赞 · 2 转发 · 1 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org帖内回复
- Dr Zachary Veitch@z_veitch
@NEJM @weldeiry Massive change in SoC for our ES-SCLC patients!!! Congrats to the authors #ESMO2026
来源：NEJM · x.com